62 results about "Retrobulbar optic nerve" patented technology

Methods for analyzing retinal tomography maps to detect patterns of optic nerve diseases such as glaucoma, optic neuritis, anterior ischemic optic neuropathy are disclosed in this invention. The areas of mapping include the macula centered on the fovea, and the region centered on the optic nerve head. The retinal layers that are analyzed include the nerve fiber, ganglion cell, inner plexiform and inner nuclear layers and their combinations. The overall retinal thickness can also be analyzed. Pattern analysis are applied to the maps to create single parameter for diagnosis and progression analysis of glaucoma and optic neuropathy.

Methods for analyzing retinal tomography maps to detect patterns of optic nerve diseases such as glaucoma, optic neuritis, anterior ischemic optic neuropathy are disclosed in this invention. The areas of mapping include the macula centered on the fovea, and the region centered on the optic nerve head. The retinal layers that are analyzed include the nerve fiber, ganglion cell, inner plexiform and inner nuclear layers and their combinations. The overall retinal thickness can also be analyzed. Pattern analysis are applied to the maps to create single parameter for diagnosis and progression analysis of glaucoma and optic neuropathy.

Devices and methods to deliver microcurrent stimulation therapy to the human body, when connected to a micro-stimulation current-generating apparatus. The method of applying microcurrent stimulation therapy to key points around the eye for treatment of problems such as macular degeneration, retinitis pigmentosa, glaucoma, optic neuritis and other eye-related or nerve-related conditions, as well as other diseases, such as Bell's Palsy, requiring localized stimulation to the eyes and / or on other body parts.

The invention provides an eyesight-recovering traditional Chinese medicine for treating optic neuritis and optic nerve atrophy, which belongs to Chinese herbal medicine. The eyesight-recovering traditional Chinese medicine comprises the following raw material medicines: 3g to 10g of white peony root, 3g to 9g of angelica, 10g to 15g of glossy privet fruit, 9g to 15g of mulberry fruit, 3g to 10g of rhizoma ligustici wallichii, 3g to 15g of radix salviae miltiorrhizae, 10g to 15g of rehmannia root, 10g to 15g of radix puerariae, 15g to 30g of mother-of-pearl, 9g to 15g of one-leaf wormwood, 6g to 15g of feverfew, 9g to 15g of cassia seed, 5g to 9g of Chinese wolfberry, 3g to 15g of moxibustion astragalus root, 1.5g to 5g of Chinese magnoliavine, 6g to 10g of pipewort flos eriocauli, 10g to 30g of yiren, 6g to 12g of vegetable sponge, 3g to 10g of carapax amydae and 9g to 15g of malt.

The present invention relates to a medicament comprising the compound of formula (I) wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and / or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).

The invention discloses a Chinese herba preparation for treating eye inflammation and a preparation method of the traditional Chinese preparation. The Chinese herba preparation is prepared by cassia occidentalis, concha haliotidis, bat dung, centipeda minima, emilia sonchifolia, pipewort, feather cockscomb seeds, wild chrysanthemum flower, rehmannia glutinosa, Chinese yam, pulp of dogwood fruit, rhizoma alismatis, tuckahoe, cortex moutan radicis, wolfberry, cape jasmine, mother of pearl, scouring rush, bamboo shavings, caltrop and roots of hairy asiabell. The Chinese herba preparation is a Chinese medicinal herb preparation, and has a good treatment effect for acute or chronic conjunctivitis, central retinitis and optic neuritis, and after the Chinese herba preparation is clinically used for treating more than totally 100 cases of eye diseases of more than 600 patients for more than ten years, effective rate can be higher than 90%. In addition, according to clinical verifications, the Chinese herba preparation does not cause drug resistance and does not have toxic and side effects.

A method and apparatus for administering eye tests to identify cone sensitivity loss associated with hereditary and acquired color vision loss which may be used for early detection, progress, treatment, and monitoring of eye conditions, traumatic brain injury, optic neuritis, systemic and neurological diseases including Glaucoma, Retinopathy, Age-Related Macular Degeneration, Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease and retinal toxicity. Particularly, the method and apparatus disclosed uses a Cone Contrast Test (CCT) to test individuals for hereditary or acquired color vision loss associated with (a) early signs of potential disease / damage / toxicity in an effort to (i) provide opportunity for treatment, and (ii) prevent permanent eye damage, and (b) monitor progress and treatment of such disease / damage / toxicity. The system comprises a computer system including an input device and a display device, and the accuracy and repeatability of the testing is provided by repeated calibration using a colormeter.

2-Chloro-2′-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO-IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity.

Mycobacterium w or its components are found to have poly TLR antagonistic activity to induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in management of diseases wherein TLRs are over expressed, like sepsis, multiple sclerosis, optic neuritis, Chronic obstructive pulmonary diseases multiple myeloma etc.

The invention discloses a biological diagnosis marker for central nervous system demyelinating diseases. The biological diagnosis marker refers to platelet-derived growth factors, chemotactic factors 12 and chemotactic factors 14 in cerebrospinal fluid. The central nervous system demyelinating diseases include optic neuritis (ON) and neuromyelitis optica (NMO); disease changes can be evaluated by monitoring the platelet-derived growth factor and the chemotactic factors in cerebrospinal fluid in different phases of the optic neuritis ON so as to judge recovering conditions. A new biological marker can be discovered by detecting levels and changes of platelet-derived growth factors, chemotactic factors 12 and chemotactic factors 14 in cerebrospinal fluids of ON and NMO patients, so that the medullar sheath regeneration capability can be estimated, an experimental basis is provided for the ON and NMO recovery and development, and a new idea is provided for treatment.

The present invention is related to a method, system or process for screening, studying and treating disorders which have a component of mercurial including: autism, autism spectrum disorders, ADD, ADHD, mental retardation, Asperger's syndrome, childhood psychoses, stammering, stuttering, tics, repetitive movements, eating disorders, sleep disorders, enuresis, disturbances of emotion, developmental language disorders, developmental speech disorders, developmental delay, Alzheimer's disease, diabetes, heart disease, obesity, ALS, nephritic syndrome, renal failure, asthma, systemic lupus, autoimmune thyroiditis, rheumatoid arthritis, arthritis, vasculitis, myelitis, glomerulonephritis, optic neuritis, infantile cerebral palsy, epilepsy, migraine, toxic encephalopathy, polyneuropathy, cerebral degenerations, anterior horn cell disease, spinocerebellar disease, extrapyramidal disease, and myopathy, and other related disorders. The invention of a method of screening, studying and treating of these disorders by utilizing the interaction of mercurial with the steroidgenesis pathway and its control by the hypothalamus-pituitary-adrenal axis is described.

The invention is directed to methods for preventing and / or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and / or treating optic neuritis and / or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and / or and Amnion-derived Multipotent Progenitor (AMP) cell compositions.

The invention relates to TACI-Immunoglobulin fusion proteins for the treatment of optic neuritis.

The invention discloses a traditional Chinese medicine preparation for treating acute optic neuritis, as well as a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials in certain weight proportion: ramulus uncariae cum uncis, semen cassiae, dendrobium, concha haliotidis, feaces vespetilio, flos eriocauli, radix angelicae sinensis, cornus fruit, amber, orange fibers, pelargonium hortorum bailey, rehmanniae praeparatum, juncus pith, root poria, Chinese ginseng, cornu saigae tataricae, fructus forsythiae, radix scutellariae, radix glycyrrhizae and mint. The traditional Chinese medicine preparation has the effects of removing heat from the liver to discharge fire, soothing the liver and relieving depression, improving eyesight and removing slight cornea opacity, promoting blood circulation to remove meridian obstruction, nourishing yin for lowering fire, and tranquilizing mind, and can effectively treat acute optic neuritis.

The invention relates to a traditional Chinese medicine composition for treating acute optic neuritis. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 10-30 parts of tribulusterrestris, 5-25 parts of flatstem milkvetch seeds, 10-30 parts of selfheal, 5-25 parts of arabic cowry shell, 5-20 parts of fructu broussonetiae, 5-25 parts of radix salviae miltiorrhizae, 5-20 parts of rheum officinale, 5-20 parts of centipeda minima, 5-25 parts of fruits of polygonum orientale, 5-20 parts of albizia flowers, 5-25 parts of rhizoma picrorhizae, 10-30 parts of Carthamus tinctorus L, 5-20 parts of rhizoma chuanxiong, 5-20 parts of dendrobe, 10-30 parts of shepherd's purse, 5-20 parts of herb of variegate ladyslipper, 5-25 parts of semen plantaginis, 5-20 parts of folium mori, 5-20 parts of babysbreath, 10-30 parts of senecio scandens, 5-20 parts of rhizoma anemarrhenae, and 5-15 parts of liquorice. The traditional Chinese medicine composition has the efficacies of tonifying liver and kidney, resolving stagnation for tranquilization, clearing liver-fire, activating blood and removing stasis, removing nebula for improving eyesight, nourishing yin and clearing heat, and relieving swelling and pain, and has significant curative effects and reliable effects in treating acute optic neuritis.

The invention relates to the field of medical apparatus and instruments, in particular to a retrobulbar optic nerve exposer specially made for an optic nerve sheath windowing operation. The retrobulbar optic nerve exposer comprises a handle and a blunt body, wherein the blunt body is fixedly arranged at the front end of the handle; the blunt body is a flat arc; the front end of the blunt body is forked; and inner and outer edges of the blunt body are smooth. According to the retrobulbar optic nerve exposer provided by the invention, retrobulbar optic nerves at the back of eyeballs can be conveniently and safely probed, and surrounding tissues of the optic nerves are accurately and firmly pushed aside, so that the optic nerves are exposed, and the windowing operation can be conveniently performed on optic nerve sheaths by using an incision knife subsequently.

An isolated polynucleotide encoding human glutamate cysteine ligase and human glutathione synthase, as well as expression constructs, vectors and pharmaceutical compositions comprising the same, are provided herein. Methods for use of these compositions in the treatment oxidative stress related diseases, including, for example, atherosclerosis, Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, diabetes, chronic lung disease, diseases associated with mitochondrial dysfunction, diseases associated with chronic inflammation, retinitis pigmentosa, wet age related macular degeneration, dry age related macular degeneration, diabetic retinopathy, Lebers optic neuropathy, and optic neuritis are also provided.

The invention relates to the field of biological detection and particularly relates to a molecular marker circRNA for diagnosing idiopathic optic neuritis, a kit and application. Detection is carriedout by employing a circRNA chip so as to acquire an abnormal-expressed circRNAs expression profile of cerebrospinal fluid, verification is carried out by applying a qRT-PCR method, and thus, the molecular marker circRNA has a tight design and a mature evaluation system. The condition that hsa_circ_0007503 in the cerebrospinal fluid serves as an important biological detection index is discovered for the first time, the detection index is minimally-invasive and cheap and can be extensively applied to clinical detection, and the problems of clinical diagnosis on the idiopathic optic neuritis thatthe time is long, the process is tedious, the cost is relatively high, and the sensitivity is low are solved. A new way of think is provided for diagnosing the idiopathic optic neuritis, and meanwhile, a novel direction is provided for completing pathogenesis and a treatment target point of the idiopathic optic neuritis.

The invention discloses a Chinese medicine composition for treating a fundi disease. The Chinese medicine composition is prepared from the following Chinese medicinal herbs in parts by weight: 40-50 parts of fel ursi, 40-50 parts of rhizoma coptidis from Sichuan of China, 40-50 parts of butterflybush flower, 40-50 parts of notopterygium root, 25-35 parts of pillis ophidiae, 25-35 parts of cortex lycii radicis, 25-35 parts of herba epimedii, 25-35 parts of equisetum hyemale, 25-35 parts of felwort, 10-20 parts of inula flower, 10-20 parts of chamomile flower, 10-20 parts of dianthus superbus, 6-13 parts of nux prinsepiae, 3-9 parts of dragon's blood, 3-9 parts of fructus viticis and 500-1500 parts of fresh wether liver. The Chinese medicine composition can be used for treating fundi diseases caused by any reasons, especially has a special effect of treating symptoms such as retinal arterial obstruction, retinal vein obstruction, optic neuritis, retinal detachment, macular degeneration and the like. Through repeated clinical verifications, the Chinese medicine composition is accurate in treatment effect, good in effect, short in treatment course, high in effect taking speed, and free from side and toxic effects.

This document provides materials and methods for treating a damaged optic nerve in a mammal to restore visual function comprising administering a population of induced pluripotent stem cell-derived oligodendrocyte precursor cells. This document also provides materials and methods for determining a remyelination potential quotient of a population of induced pluripotent stem cell-derived oligodendrocyte precursor cells. This document also provides materials and methods for screening factors that enhance maturation or myelination efficiency of an induced pluripotent stem cell-derived oligodendrocyte precursor cell or cells.

The invention discloses a traditional Chinese medicine preparation for treating optic neuritis and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The active ingredients of the traditional Chinese medicine preparation are prepared from the following raw materials: zamioculcas zamiifolia, eastern bracken fern rhizome, cocklebur fruits, garden balsam stems, leaves of Chinese loropetalum, barks of tangut barberries, omei meadowrue herb, myrrh, selfheal, japanese violet herb or roots, lepironia articulate, uniflower swisscentaury roots, senna septemtrionalis, common cockscomb seeds, pearls ad sophora flowers. The medicinal materials selected for the traditional Chinese medicine preparation are reasonably combined and meet the research theory of traditional Chinese medicines and modern medicines, so that the preparation has the functions of clearing liver and improving vision, expelling pus and dispersing swelling, diminishing inflammation and relieving pain and clearing away heat and toxic materials and is convenient to use, good in absorption effect and free of adverse reactions and toxic and side effects. Clinical verifications show that the preparation can be used for removing eye opacity and improving eyesight, cooling blood and clearing liver, clearing heat and promoting diuresis and improving internal and external environments of a human body so as to treat or alleviate various symptoms of optic neuritis and is suitable for clinical treatment and nursing popularization and application for optic neuritis.

Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy.

The invention discloses a multi-element integral vision and vertebral column correction method which comprises the following steps: I, massaging the back; II, massaging the head; III, massaging the face; IV, performing moxa-moxibustion treatment; V, massaging shoulders and the neck; VI, massaging sole reflection regions; VII, massaging ears; VIII, performing physical massage; IX, massaging eyes; and X, correcting the vertebral column. On the theoretical basis of traditional Chinese medicines, the method has an additional holographic therapeutic method of the sole reflection regions, the facesand the ears, and a plant physical therapeutic method as well, a comprehensive physical therapy effect can be achieved through main and collateral channels, acupuncture points, plant essential oil, hot compressing of medicines and pure physical artificial massage and dredging together with self assisted exercise, and not only is juvenile myopia effectively treated, but also juvenile vertebral column correction can be assisted; and in addition, eye dryness, eye fatigue, iriditis, xerophthalmia, hordeolum, retinitis pigmentosa, macular degeneration, optic neuritis and strabismus can be effectively treated.

The invention relates to optic neuritis drug research, in particular to an application of sesquiterpene lactone compounds in preparation of optic neuritis treatment drugs, and the sesquiterpene lactone compounds and pharmaceutically acceptable auxiliary materials are prepared into a medicament. The research finds that ACT001 can effectively inhibit the inflammatory response of microglia, and can significantly reduce the release of inflammatory factors including NO, TNF-alpha and IL-6. The effect of inhibiting BV2 cell proliferation is achieved. The compound has a good curative effect on opticneuritis, especially optic neuromyelitis.

The invention relates to a traditional Chinese medicine prescription for treating optic neuritis in the neurology department. The traditional Chinese medicine prescription is prepared from traditional Chinese medicine raw materials in parts by weight as follows: 7-20 parts of downy rosemyrtle roots, 5-10 parts of roots of syzygium buxifolium, 10-15 parts of herbs of creeping sage, 10-20 parts of lotus stamen, 3-10 parts of conic gymnadenia tubers, 5-8 parts of bicolor lespedeza, 3-7 parts of featherleaf rodgersflowers, 10-15 parts of begonia roots, 5-12 parts of herbs of stickyhair pearleverlasting, 10-20 parts of Korean raspberry roots, 10-20 parts of seabuckthorn fruits, 5-20 parts of flaccid knotweed herbs, 3-8 parts of herbs of blacken saussurea, 5-10 parts of herbs of lyrate bittercres, 10-15 parts of glabrousleaf pittosporum roots, 10-15 parts of long lepisorus, 3-8 parts of yunnan madder roots and 8-15 parts of tatarian aster roots. The traditional Chinese medicine prescription adopts compatible medicines, has effects of tonifying the liver and the kidney, promoting the circulation of qi, inducing resuscitation, nourishing blood and dredging collaterals, takes effect rapidly when used for treating optic neuritis, has remarkable curative effect and high cure rate and is safe and free of toxic and side effects, and optic neuritis is not prone to relapse.

The invention provides an ophthalmic preparation for treating macular edema, optic neuritis and non-infectious entophthalmia. The ophthalmic preparation is composed of an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material; the active ingredientfor treating the eye diseases is a glucocorticoid medicine and / or a non-steroidal medicine; the ophthalmic preparation carrier or auxiliary material comprises the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with medium polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and / or the non-steroidal medicines to penetrate through the anterior segment of the eye and be conveyed to the posterior segment of the eye to treat the macular edema, the optic neuritis and the non-infectious entophthalmiain an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and very positive social significance.